Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2018 2
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. Purcell JW, et al. Among authors: morgan lappe se. Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764866
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S, Serwer L, DuPage A, Elkins K, Chauhan N, Ravn M, Buchanan F, Wang L, Krimm M, Wong K, Sagert J, Tipton K, Moore SJ, Huang Y, Jang A, Ureno E, Miller A, Patrick S, Duvur S, Liu S, Vasiljeva O, Li Y, Henriques T, Badagnani I, Jeffries S, Schleyer S, Leanna R, Krebber C, Viswanathan S, Desnoyers L, Terrett J, Belvin M, Morgan-Lappe S, Kavanaugh WM, Richardson J. Singh S, et al. Among authors: morgan lappe s. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193. Mol Cancer Ther. 2022. PMID: 35666803 Free PMC article.
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Tahir SK, et al. Among authors: morgan lappe s. Blood. 2023 Apr 27;141(17):2114-2126. doi: 10.1182/blood.2022017333. Blood. 2023. PMID: 36720090 Free PMC article.
ABBV-319: A CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
Chang CA, Emberley E, D'Souza AL, Zhao W, Cosgrove C, Parrish KE, Mitra D, Payson E, Oleksijew A, Ellis P, Rodriguez L, Duggan R, Hrusch C, Lasko L, Assaily W, Zheng P, Liu W, Hernandez A Jr, McCarthy K, Zhang Z, Rha G, Cao Z, Li Y, Perng O, Campbell J, Zhang G, Curran TS, Bruncko M, Marvin CC, Hobson AD, McPherson M, Uziel T, Pysz MA, Zhao X, Bankovich A, Hayflick J, McDevitt M, Freise KJ, Morgan-Lappe S, Purcell JW. Chang CA, et al. Among authors: morgan lappe s. Blood. 2024 May 3:blood.2024023849. doi: 10.1182/blood.2024023849. Online ahead of print. Blood. 2024. PMID: 38701407
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, Carneiro BA, Devriese LA, Petrich A, Modi D, Morgan-Lappe S, Nuthalapati S, Motwani M, Dunbar M, Glasgow J, Medeiros BC, Calvo E. LoRusso P, et al. Among authors: morgan lappe s. Invest New Drugs. 2022 Aug;40(4):762-772. doi: 10.1007/s10637-022-01247-1. Epub 2022 Apr 25. Invest New Drugs. 2022. PMID: 35467243 Free PMC article. Clinical Trial.
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW Jr, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. Gordon MS, et al. Among authors: morgan lappe se. Mol Cancer Ther. 2021 Oct;20(10):1988-1995. doi: 10.1158/1535-7163.MCT-20-0985. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315767 Free PMC article. Clinical Trial.
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors.
Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE. Phillips DC, et al. Among authors: morgan lappe se. Cancer Res. 2021 Jun 15;81(12):3402-3414. doi: 10.1158/0008-5472.CAN-20-2178. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687950
ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
Li Y, Hickson JA, Ambrosi DJ, Haasch DL, Foster-Duke KD, Eaton LJ, DiGiammarino EL, Panchal SC, Jiang F, Mudd SR, Zhang C, Akella SS, Gao W, Ralston SL, Naumovski L, Gu J, Morgan-Lappe SE. Li Y, et al. Among authors: morgan lappe se. Mol Cancer Ther. 2018 May;17(5):1039-1050. doi: 10.1158/1535-7163.MCT-17-0800. Epub 2018 Mar 28. Mol Cancer Ther. 2018. PMID: 29592882
12 results